NQO1 and metabolic syndrome: Bromocriptine-QR treatment also reduced the mRNA expression of both the master antioxidant gene regulators, OXR1, NRF2, and NQO1, as well as multiple down-stream antioxidant target genes including SOD1, CAT, GPX1, GPX4, GCH1 (that act collectively to combat cellular elevations in ROS), and HMOX1 that are elevated in metabolic syndrome conditions [114,115,116,117,118,119,120,121,122,123,124,125,126].